Company Overview and News

 
Namaste Receives Conditional Approval to List on TSX Venture Exchange

5h globenewswire
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has received conditional approval to list the common shares and warrants of the Company on the TSX Venture Exchange (“TSXV”) as a Tier 1 issuer. The listing is subject to the Company fulfilling certain requirements of the TSXV in accordance with the terms of its conditional approval letter dated April 18th, 2018.
Upvote Downvote

 
Namaste Announces Ammendment to LOI With 2624078 Ontario Inc. to Include Application for ACMPR Medical Cannabis Oil Production and Sales Licence

2018-04-09 globenewswire
VANCOUVER, British Columbia, April 09, 2018 (GLOBE NEWSWIRE) -- Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that the Company has signed an amendment to the Letter of Intent (“LOI”) dated April 4th, 2018 (the “LOI Amendment”). Under the terms of the LOI Amendment, 2624078 Ontario Inc. will apply for an Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license to produce and sell medical cannabis oils (the “ACMPR Licence”).
Upvote Downvote

 
CORRECTING and REPLACING -- Namaste Announces March 2018 Sales of C$1.24M Representing a 74% Year-on-Year Increase and Acquires 535 New Patients Representing a 142% Month-on-Month Increase

2018-04-06 globenewswire
Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce March 2018 total unaudited net revenue as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,249,670, representing a 74% revenue increase in March 2018 when compared to March 2017. Namaste’s management team is also pleased to report that the Company’s wholly owned subsidiary, Namaste MD Inc.
Upvote Downvote

 
Namaste Announces February 2018 Sales of C$1.24M Representing a 74% Year-on-Year Increase and Acquires 535 New Patients Representing a 142% Month-on-Month Increase

2018-04-06 globenewswire
Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce March 2018 total unaudited net revenue as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,249,670, representing a 74% revenue increase in March 2018 when compared to March 2017. Namaste’s management team is also pleased to report that the Company’s wholly owned subsidiary, Namaste MD Inc.
Upvote Downvote

 
Namaste Announces Canada’s First Large-Scale National Prospective Observational Study to Observe the Impact of Medical Cannabis Use for Anxiety Treatment

2018-04-04 globenewswire
VANCOUVER, British Columbia, April 04, 2018 (GLOBE NEWSWIRE) -- Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT: M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants.
Upvote Downvote

 
Namaste Announces Appointment of Laurens Feenstra, Branden Spikes and Don Nickless to Board of Directors

2018-03-28 globenewswire
VANCOUVER, British Columbia, March 28, 2018 (GLOBE NEWSWIRE) -- Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that following the company’s Annual General Meeting of shareholders (“AGM”), which was held at the law offices of Gowling WLG (Canada) LLP on Tuesday, March 27, 2018, the Company has appointed Branden Spikes, Laurens Feenstra and Donald William Nickless (the “Board Appointees”) for positions on Namaste’s 2018 board of directors.
Upvote Downvote

1
Namaste Technologies Could Become The Amazon Of The Cannabis Sector

2018-03-25 seekingalpha
Namaste Technologies Inc. (OTCQB:NXTTF) is considered among the leading, if not the top, e-commerce company for delivery of medical cannabis systems around the world.
Upvote Downvote

 
Namaste Receives ACMPR Medical Cannabis Production License

2018-03-16 globenewswire
VANCOUVER, British Columbia, March 16, 2018 (GLOBE NEWSWIRE) -- Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that its wholly owned subsidiary, Cannmart Inc. (“Cannmart”) has received its Access to Cannabis for Medical Purposes Regulations (“ACMPR”) Production License (the “License”). Under the guidelines set forth by Health Canada, Cannmart may now place initial orders with ACMPR licensed producers.
Upvote Downvote

 
Inolife R&D Signs Letter of Intent With Namaste to Research the Use of Needle-Free Injection Technologies With Medical Cannabis

2018-03-13 accesswire
TORONTO, ON / ACCESSWIRE / March 13, 2018 / Inolife R&D Inc. ("Inolife"), is pleased to announce today it has signed a letter of intent with Namaste Technologies Inc. ("Namaste") for trials in the use of Inolife's needle-free technologies for the dosing and administration of medical cannabis.
Upvote Downvote

 
Can Supreme Cannabis Differentiate With Branding And B2B Model?

2018-02-26 seekingalpha
As demand for medical and recreational cannabis increases, the overall industry has engaged in different strategies and tactics in an attempt to differentiate from one another, so the sector isn't considered a commodity business that competes only on price. Under that scenario there wouldn't be many profitable producers.
Upvote Downvote

 
Supreme Cannabis Is Way Overvalued

2018-02-23 seekingalpha
I came across Supreme Cannabis (OTCPK:SPRWF) as I was looking around for value opportunities to invest in after the sell-off from a few weeks ago and this company showed up on my search. And after digging into its financials I was quite surprised about how overvalued the stock is.
Upvote Downvote

1
Emerald Health: West Coast Cannabis Player With Biotech Focus

2018-02-05 seekingalpha
Our followers would have read our Weekly Cannabis Report in which we started tracking weekly performance of 11 cannabis companies, in addition to providing a weekly update on the latest news and developments in the sector. Starting today we are rolling out our initiating reports for the 11 names that we cover in order to offer deeper insights and analysis for our readers.
Upvote Downvote

 
Namaste Announces Increase in Bought Deal Offering to $35 Million

2018-02-01 marketwired
Namaste Technologies Inc. (CSE:N)(CSE:N.CN)(CNSX:N)(FRANKFURT:M5BQ)(OTCQB:NXTTF) ("Namaste" or the "Company"), is pleased to announce that it has entered into an amended letter of engagement with Eight Capital and Canaccord Genuity Corp. as co-lead underwriters and joint bookrunners, and including Beacon Securities Limited (together, the "Underwriters"), under which the Underwriters have now agreed to purchase 13,726,000 units of the Company (the "Units"), on a "bought deal" basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $2.
Upvote Downvote

 
Namaste Enters Into $30 Million Bought Deal Equity Financing

2018-02-01 marketwired
Namaste Technologies Inc. (CSE:N)(CSE:N.CN)(CNSX:N)(FRANKFURT:M5BQ)(OTCQB:NXTTF) ("Namaste" or the "Company"), is pleased to announce that it has entered into a letter of engagement with Eight Capital, under which Eight Capital has agreed to purchase, as sole bookrunner and lead underwriter, along with a syndicate of underwriters (the "Underwriters"), 11,765,000 units of the Company (the "Units"), on a "bought deal" basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $2.
Upvote Downvote

1
261 Marijuana Stocks: Jeff Slowed Us Down, But 32% In Less Than 30 Days Is Not Bad

2018-01-30 seekingalpha
In January 2017, the cannabis or marijuana stocks and sector generated a return of about 51%.
Upvote Downvote

NXTTF: Namaste Technologies Inc (CNSX:N) Analysis and Research Report

2018-02-04 - Asif

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience. Description of the business Dollinger E...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...